BRK-B vs BXMX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
BXMX presents a classic value trap profile: fundamentally undervalued but technically bearish. The Piotroski F-Score of 5/9 indicates stable financial health, and the stock trades at a significant discount to both its Graham Number ($26.91) and Intrinsic Value ($59.0). While the P/B ratio of 0.82 and low Debt/Equity (0.01) are highly attractive, the 0/100 technical trend and negative revenue growth suggest a lack of market conviction.
Compare Another Pair
Related Comparisons
BRK-B vs BXMX: Head-to-Head Comparison
This page compares Berkshire Hathaway Inc. (BRK-B) and Nuveen S&P 500 Buy-Write Income Fund (BXMX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.